Search Results - "Estevam, Jose"

Acknowledging the Emergence of a New Logic: The Regulation of Healthcare in Brazil by Ryngelblum, Arnaldo, Freitas, José Estevam, Costa Maroni Saraiva, Mayla Cristina

“…Studies of institutional change have focused on several themes. Yet, examinations of small innovations still require attention. This question is important…”
Get full text

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma by Kumar, Shaji, Flinn, Ian, Richardson, Paul G., Hari, Parameswaran, Callander, Natalie, Noga, Stephen J., Stewart, A. Keith, Turturro, Francesco, Rifkin, Robert, Wolf, Jeffrey, Estevam, Jose, Mulligan, George, Shi, Hongliang, Webb, Iain J., Rajkumar, S. Vincent

“…Combinations of bortezomib (V) and dexamethasone (D) with either lenalidomide (R) or cyclophosphamide (C) have shown significant efficacy. This randomized…”
Get full text

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study by Kumar, Shaji K, Prof, Berdeja, Jesus G, MD, Niesvizky, Ruben, Prof, Lonial, Sagar, Prof, Laubach, Jacob P, MD, Hamadani, Mehdi, MD, Stewart, A Keith, Prof, Hari, Parameswaran, Prof, Roy, Vivek, MD, Vescio, Robert, MD, Kaufman, Jonathan L, MD, Berg, Deborah, MSN, Liao, Eileen, PhD, Di Bacco, Alessandra, PhD, Estevam, Jose, BSc, Gupta, Neeraj, PhD, Hui, Ai-Min, MD, Rajkumar, Vincent, Prof, Richardson, Paul G, Prof

“…Summary Background The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib…”
Get full text

Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects by Fedyk, Eric R., Zhao, Lin, Koch, Annelize, Smithson, Glennda, Estevam, Jose, Chen, Grace, Lahu, Gezim, Roepcke, Stefan, Lin, Jianchang, Mclean, Lachy

“…Aims This investigation characterised tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 antibody TAK‐079. Methods A randomised,…”
Get full text

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo by Gallery, Melissa, Zhang, Julie, Bradley, Daniel P, Brauer, Pamela, Cvet, Donna, Estevam, Jose, Danaee, Hadi, Greenfield, Edward, Li, Ping, Manfredi, Mark, Loke, Huay-Keng, Rabino, Claudia, Stringer, Brad, Williamson, Mark, Wyant, Tim, Yang, Johnny, Zhu, Qing, Abu-Yousif, Adnan, Veiby, O Petter

“…Guanylyl cyclase C (GCC) is a cell-surface protein that is expressed by normal intestinal epithelial cells, more than 95% of metastatic colorectal cancers…”
Get full text

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma by San-Miguel, Jesús F, Echeveste Gutierrez, Maria-Asunción, Špicka, Ivan, Mateos, María-Victoria, Song, Kevin, Craig, Michael D, Bladé, Joan, Hájek, Roman, Chen, Christine, Di Bacco, Alessandra, Estevam, Jose, Gupta, Neeraj, Byrne, Catriona, Lu, Vickie, van de Velde, Helgi, Lonial, Sagar

“…This phase I/II dose-escalation study investigated the all-oral ixazomib-melphalan-prednisone regimen, followed by single-agent ixazomib maintenance, in…”
Get full text

Protocol for measurement of enamel loss from brushing with an anti-erosive toothpaste after an acidic episode by Dehghan, Mojdeh, Vieira Ozorio, Jose Estevam, Chanin, Simon, Tantbirojn, Daranee, Versluis, Antheunis, Garcia-Godoy, Franklin

“…Tooth erosion from an acidic insult may be exacerbated by toothbrushing. The purposes of this study were to develop an in vitro methodology to measure enamel…”
Get more information

Oral soft tissue lipomas: a case series by Bandéca, Matheus Coêlho, de Pádua, Joubert Magalhães, Nadalin, Michele Regina, Ozório, José Estevam Vieira, Silva-Sousa, Yara Terezinha Corrêa, da Cruz Perez, Danyel Elias

“…Lipomas are relatively uncommon tumours in the oral cavity; only 1% to 4% of cases occur at this site. In this study, we describe the clinical and…”
Get full text

Advancing Point-of-Care Applications with Droplet Microfluidics: From Single-Cell to Multicellular Analysis by Sharkey, Christina, White, Rachel, Finocchiaro, Michael, Thomas, Judene, Estevam, Jose, Konry, Tania

“…Recent advances in single-cell and multicellular microfluidics technology have provided powerful tools for studying cancer biology and immunology. The ability…”
Get full text

Mezagitamab Induces Immunomodulatory Effect in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) by Abadier, Michael, Estevam, Jose, Berg, Deborah, Fedyk, Eric Robert

“…Background Mezagitamab is a fully human immunoglobulin (Ig) G1 monoclonal antibody with high affinity to CD38 that depletes tumor cells expressing CD38 by…”
Get full text

New thermal study of polymerization and degradation kinetics of methylene diphenyl diisocyanate by da Silva, José Eduardo Estevam, Alarcon, Rafael Turra, Gaglieri, Caroline, Magdalena, Aroldo Geraldo, da Silva-Filho, Luiz Carlos, Bannach, Gilbert

“…This work investigates the thermal polymerization process of a methylene diphenyl diisocyanate (MDI) monomer as well as its thermal degradation following the…”
Get full text

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials by Paiva, Bruno, Manrique, Irene, Dimopoulos, Meletios A., Gay, Francesca, Min, Chang-Ki, Zweegman, Sonja, Špička, Ivan, Teipel, Raphael, Mateos, María-Victoria, Giuliani, Nicola, Cavo, Michele, Hopkins, Christine Rojas, Fu, Weijun, Suryanarayan, Kaveri, Vorog, Alexander, Li, Cong, Wang, Bingxia, Estevam, Jose, Labotka, Richard, Dash, Ajeeta B.

“…•Conversion from MRD− to MRD+ or from MRD+ to MRD− status during ixazomib or placebo maintenance modulates the risk of disease progression.•Ixazomib prolonged…”
Get full text

Elifacs: A Multiplex Assay to Detect Antigen Specific T Cells and to Monitor the Immune Response by Raddassi, Khadir, Research Instructor, Brigham and Women's Hospital, Neurology, Boston, MA, Bouchier, Kasia, Scientist, Immune Tolerance Network, San Francisco, CA, Estevam, Jose, Research Assistant, Brigham and Women's Hospital, Neurology, Boston, MA, Seyfert-Margolis, Vicki, Scientist, Immune Tolerance Network, San Francisco, CA, Hafler, David, Lab Director, Brigham and Women's Hospital, Neurology, Boston, MA

Get full text

Improving Elispot to Detect Antigen Specific T Cells by Raddassi, Khadir, Research Instructor, Brigham and Women's Hospital, Neurology, Boston, MA, Bourcier, Kasia, Scientist, Immune Tolerance Network, San Francisco, CA, Estevam, Jose, Research Assistant, Brigham and Women's Hospital, Neurology, Boston, MA, Seyfert-Margolis, Vicki, Scientist, Immune Tolerance Network, San Francisco, CA, Hafler, David, Lab Director, Brigham and Women's Hospital, Neurology, Boston, MA

Get full text

Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab by Wyant, Tim, Estevam, Jose, Yang, Lili, Rosario, Maria

“…Background Vedolizumab is a monoclonal antibody approved for use in ulcerative colitis and Crohn's disease. By specifically binding to α4β7 integrin,…”
Get full text

A Single Administration of the Cytolytic CD38 Antibody TAK-079 to Healthy Subjects: Tolerability, Pharmacokinetics and Pharmacodynamics by Fedyk, Eric Robert, Berg, Deborah, Smithson, Glenda, Estevam, Jose, Mclean, Lachy, Allikmets, Kristina, Palumbo, Antonio

“…Background: A study investigating the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of TAK-079 administered subcutaneously as a single…”
Get full text

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma by Richardson, Paul G., Hofmeister, Craig C., Rosenbaum, Cara A., Htut, Myo, Vesole, David H., Berdeja, Jesus G., Liedtke, Michaela, Chari, Ajai, Smith, Stephen D., Lebovic, Daniel, Raje, Noopur, Byrne, Catriona, Liao, Eileen, Gupta, Neeraj, Bacco, Alessandra Di, Estevam, Jose, Berg, Deborah, Baz, Rachid

“…Summary Weekly ixazomib with lenalidomide‐dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma (NDMM) patients. This phase…”
Get full text

Development and validation of a high‐parameter mass cytometry workflow to decipher immunomodulatory changes in celiac disease by Estevam, Jose, Krutzik, Peter, Vander Tuig, Jason, McAuliffe, William J., Smithson, Glennda

“…The advent of time‐of‐flight mass cytometry (CyTOF) has enabled high dimensional and unbiased examination of the immune system to simultaneous interrogate a…”
Get full text

The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells by Fedyk, Eric Robert, Idamakanti, Neeraja, Chen, Jia, Estevam, Jose, Hernandez, Vivian, Wagoner, Matthew, Carsillo, Mary, Berg, Deborah, Allikmets, Kristina, Lahu, Gezim, Palumbo, Antonio

“…Introduction: The CD38 antigen is a target for treating multiple myeloma and is being investigated for disorders caused by plasma cells. Therapeutics bind to…”
Get full text

Standardized propolis extract and calcium hydroxide as pulpotomy agents in primary pig teeth by Ozório, José Estevam Vieira, Carvalho, Luiz Fernando de Oliveira E Silva, de Oliveira, Danilo Alessandro, de Sousa-Neto, Manoel Damião, Perez, Danyel Elias da Cruz

“…The purpose of this study was to evaluate the histological features of the pulp tissue in primary pig teeth submitted to pulpotomy and capped with calcium…”
Get more information